BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaMatthew S. Zabriskie, Thomas O’Hare, Marina Konopleva et al.|Cancer Cell|2014Cited by 366
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyNeil P. Shah, Kristina M. Gregory, Ravi Bhatia et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 116
Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic TherapiesShiven B. Patel, Neeraj Agarwal, David D. Stenehjem et al.|Clinical Genitourinary Cancer|2015Cited by 15
CML and the WHO: Why?Ellin Berman, Brian Druker, Neil P. Shah et al.|Journal of Clinical Oncology|2023Cited by 14